Cognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812
Cognition Therapeutics, Inc. (Nasdaq: CGTX) has initiated its Phase 2 SHIMMER clinical trial for CT1812, targeting dementia with Lewy bodies (DLB). The trial, supported by a $30 million NIA grant, aims to enroll 120 adults aged 50-80 with DLB. CT1812 is an oral therapeutic intended to address DLB's underlying biology, which currently lacks disease-modifying treatments. Primary investigator Dr. James E. Galvin emphasized the trial's importance in exploring a unique mechanism of action against this severe condition.
- Initiation of Phase 2 SHIMMER trial for CT1812 signifies progress in DLB treatment research.
- Study supported by a significant $30 million grant from the National Institute on Aging.
- DLB currently has no approved disease-modifying treatments, indicating high unmet medical need.
- Potential reimbursement and market access challenges as CT1812 moves further into development.
- Study Supported by
NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) today announced that the first patient has been dosed in its double-blind, placebo-controlled, randomized Phase 2 SHIMMER clinical trial of CT1812 in patients with dementia with Lewy bodies (DLB). CT1812 is an experimental, orally delivered small molecule therapeutic intended to address the underlying biology of DLB.
“Dementia with Lewy bodies is a devastating disease that has no disease-modifying treatments and impacts millions of people around the globe, yet remains under-funded and under-researched,” stated James E. Galvin, MD, MPH, the director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine and primary investigator in the Phase 2 study. “This Phase 2 study provides me and my colleagues at other sites in the Lewy Body Dementia Consortium an opportunity to investigate a unique mechanism of action that has the potential to impact the progression of DLB. I’m looking forward to working with the team at Cognition to assess this novel medication.”
DLB is a multi-faceted disorder characterized by the accumulation of α-synuclein fibrils, the major constituent of the Lewy bodies that occur inside brain neurons, which exert deleterious effects across brain structures. In addition, many patients with DLB also have a buildup of Aβ oligomers. Together, the accumulation of pathogenic proteins in DLB is believed to be due in part to a failure of autophagy and other key cellular functions. Further evidence suggests that these processes are regulated by the sigma-2 (σ-2) receptor, which is the biological target of CT1812. Cognition has previously published results supporting the use of σ-2 receptor modulators such as CT1812 to protect neurons from the toxic insults from α-synuclein and Aβ oligomers. It is anticipated that its mechanism of action may thus enable CT1812 to address the dual assault from α-synuclein and Aβ oligomers in patients with DLB.
Cognition anticipates enrolling 120 adults between 50 and 80 years of age with a DLB diagnosis, who will be randomized to receive placebo or one of two daily (QD) doses of CT1812 for six months. In addition to safety, this study will compare changes in cognitive performance, physical activity, and pharmacokinetic and pharmacodynamic biomarkers to baseline measurements. Furthermore, cerebrospinal fluid (CSF) will be collected and analyzed for α-synuclein content and established patterns of differential protein expression.
“DLB is a poorly understood disease with no approved treatments and few active clinical research efforts. We are excited to explore the potential that our σ-2 receptor modulator, CT1812, may have therapeutic benefit for patients with this intractable disease,” added Anthony O. Caggiano, M.D., Ph.D., chief medical officer and head of R&D at Cognition Therapeutics. “Initiation of patient treatment in this interventional study is an important milestone for Cognition Therapeutics and for the DLB community. We are grateful to our collaborators at the Lewy Body Dementia Association (LBDA) and the Miller School of Medicine; as well as the continued support from the National Institute on Aging, who awarded Cognition the largest grant to date to study DLB.”
The Phase 2 SHIMMER study (COG1201) is supported by a
About Dementia with Lewy Bodies
An estimated 1.4 million Americans are living with DLB, a progressive disease that accounts for approximately 5
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com.
Editor’s note: The content is solely the responsibility of Cognition Therapeutics and does not necessarily represent the official views of the National Institutes of Health.
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions (including, but not limited to, the current status and eventual outcome of our clinical trials), some of which cannot be predicted or quantified and some of which are beyond our control. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and are available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact Information:
Cognition Therapeutics, Inc.
info@cogrx.com
Aline Sherwood (media)
Scienta Communications
asherwood@scientapr.com
Daniel Kontoh-Boateng (investors)
Tiberend Strategic Advisors, Inc.
dboateng@tiberend.com
FAQ
What is the purpose of Cognition Therapeutics' Phase 2 SHIMMER trial?
How many patients will be enrolled in the Phase 2 SHIMMER trial?
What is the significance of the $30 million grant for Cognition Therapeutics?
When did the first patient get dosed in the trial?
What are the expected outcomes of the SHIMMER trial?
